- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | IO Biotech, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| Mi | IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights | 121 | GlobeNewswire (Europe) | Primary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still expected to readout in third quarter of 2025Data... ► Artikel lesen | |
| Mi | IO Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.04. | IO Biotech, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 26.04. | IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025 | 1 | GlobeNewswire (USA) | ||
| 25.04. | IO Biotech präsentiert vielversprechende präklinische Daten zu Impfstoffkandidaten | 2 | Investing.com Deutsch | ||
| IO BIOTECH Aktie jetzt für 0€ handeln | |||||
| 25.04. | IO Biotech unveils promising vaccine preclinical data | 1 | Investing.com | ||
| 25.04. | IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170 | 2 | GlobeNewswire (USA) | ||
| 07.04. | IO Biotech, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 31.03. | IO Biotech, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 25.03. | IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 05.03. | IO Biotech stock retains Buy rating, $12 target at H.C. Wainwright | 11 | Investing.com | ||
| 04.03. | IO Biotech on track with cancer vaccine BLA for 2025 | 3 | Investing.com | ||
| 04.03. | IO Biotech auf Kurs für Krebsimpfstoff-Zulassungsantrag bis 2025 | 7 | Investing.com Deutsch | ||
| 04.03. | IO Biotech Reports 2024 Business Highlights | 159 | GlobeNewswire (Europe) | Preparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end 2025 remain on track. The trial completed enrollment... ► Artikel lesen | |
| 04.03. | IO Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.02. | IO Biotech advances cancer vaccine candidate IO112 | 3 | Investing.com | ||
| 04.02. | IO Biotech treibt Krebsimpfstoff-Kandidaten IO112 voran | 25 | Investing.com Deutsch | ||
| 04.02. | IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate | - | GlobeNewswire (USA) | ||
| 09.01. | IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer | 172 | GlobeNewswire (Europe) | -- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company... ► Artikel lesen |
Seite:
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,100 | 0,00 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
| BIOXXMED | 0,410 | 0,00 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
| VIVOSIM LABS | 1,930 | 0,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
| OCUGEN | 0,629 | -0,82 % | Ocugen Provides Business Update with First Quarter 2025 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026Anticipate... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
| BIO-GATE | 0,685 | 0,00 % | Bio-Gate startet Produkt-Launch für Tierpflege in den USA | Bio-Gate hat die Präsenz im nordamerikanischen Veterinärmarkt ausgebaut. Gemeinsam mit einem internationalen Anbieter bringt Bio-Gate neue Tierpflegeprodukte zur Haut-, Ohr- und Wundbehandlung in die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,574 | -0,69 % | Evotecs KI-Goldgrube, Defence Therapeutics Milliarden-Märkte, Novo Nordisks Diät-Revolution: So verdienen Anleger mit | Die Gesundheitsbranche befindet sich im Umbruch. Algorithmen beschleunigen die Arzneimittelforschung um Jahre, Milliarden fließen in personalisierte Therapien, und Börsen feiern Biotech-Aktien. Doch... ► Artikel lesen | |
| VAXART | 0,369 | -2,54 % | Vaxart, Inc.: Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial | SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has received approval from the Biomedical Advanced Research and Development Authority... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,063 | -3,95 % | Burcon NutraScience Corporation: Burcon Integrates Protein Technologies at Galesburg Facility | Vancouver, British Columbia--(Newsfile Corp. - April 1, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development of... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,206 | -8,85 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update | Company Seeking Conditional Approval from European Medicines Agency (EMA) for Iopofosine I 131 in Waldenstrom Macroglobulinemia based upon CLOVER WaM Phase 2 Study Data CLOVER WaM Major Response Rate... ► Artikel lesen | |
| AFFIMED | 0,530 | -100,00 % | Affimed N.V.: Affimed Announces Receipt of Nasdaq Delisting Notice | MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market | OCALA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. ("AIM" or the "Company") (OTC Pink: AIMI) - an immuno-pharma company focused on the research and development of therapeutics to... ► Artikel lesen | |
| IMMUNIC | 0,871 | -2,02 % | IMMUNIC, INC. - 10-Q, Quarterly Report | ||
| T2 BIOSYSTEMS | 0,107 | +3,38 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| CEL-SCI | 0,217 | +5,74 % | Cel-Sci GAAP EPS of -$0.08 |
IO BIOTECH INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,940 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IO BIOTECH INC finden Sie auf Wallstreet Online.